



**Helping to enable men to live
their journey to its fullest
potential**

Nasdaq: PTPI

Cautionary Note Regarding Forward-Looking Statements


This presentation includes or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based upon Petros Pharmaceuticals, Inc.'s ("Petros," "we," "our," "us" or the "Company") management's assumptions, expectations, projections, intentions and beliefs about future events. In some cases, predictive, future-tense or forward-looking words such as "intend," "plan," "may," "will," "project," "estimate," "anticipate," "believe," "expect," "continue," "potential," "opportunity," "forecast," "should" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of risks and uncertainties, including, without limitation, Petros' ability to execute on its business strategy, including its plans to develop and commercialize its product candidates; Petros' ability to comply with obligations as a public reporting company; the ability of Petros to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; the risk that the financial performance of Petros may not be as anticipated by the merger transactions that resulted in the Company's creation; risks resulting from Petros' status as an emerging growth company, including that reduced disclosure requirements may make shares of Petros common stock less attractive to investors; risks related to Petros' ability to continue as a going concern; risks related to Petros' dependence on the commercialization of a single product, Stendra®, and on a single distributor thereof; risks related to Petros' commercial supply agreement with Vivus; and risks related to Petros' ability to obtain regulatory approvals for, or market acceptance of, any of its products or product candidates. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in the joint proxy/prospectus on Form S-4 and in periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC") under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere and in other filings that the Company may make with the SEC. The Company cautions readers that the forward-looking statements included in this presentation represent our beliefs, expectations, estimates and assumptions only as of the date of hereof and are not intended to give any assurance as to future results. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, the Company cannot assess the effect of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. Accordingly, you should not unduly rely on any forward-looking statements.

The Company undertakes no obligation to update or revise any forward-looking statements contained in this presentation, whether as a result of new information, future events, a change in our views or expectations or otherwise, except as required by federal securities laws.

Petros is Delivering Growth and Value

- Petros sells Stendra® patented and trademarked prescription Erectile Dysfunction (ED) drug
- Petros quarterly revenues grew 106% from \$3.1 million in H1 2020 to \$6.5 million in H1 2021
- Stendra, licensed from Vivus, Inc., is a PDE5 inhibitor in the same class as Viagra, Cialis and Levitra
- **The global Erectile Dysfunction Drugs market is projected to reach \$4.7B by 2026, with the US driving 30% of the market at \$1.5B¹**
- Petros has a product roadmap and growth plan to capture the unmet needs of millions of men who are being underserved
- Potential to have first over-the-counter Erectile Dysfunction (ED) drug, currently under development
- Petros has an experienced management team with prior experience at GSK, Novartis and Insight Pharma
- Petros has a strong balance sheet with \$11 million in cash as of Q2 2021

106% YOY
Growth




¹ <https://www.globenewswire.com/en/news-release/2020/10/30/2117803/0/en/Global-Erectile-Dysfunction-Drugs-Market-Will-Reach-USD-2-687-6-Million-by-2026-Facts-Factors.html>


The ED Market Opportunity

30M

ED affects 30 million men in the US¹



According to some experts, Only 25% of men with ED are actually treated in the US²



One in four ED patients are under 40 years old³

Exploratory analysis of sociodemographic and clinical data from 439 consecutive patients

\$4.7B

The global ED Drugs market is forecast to grow to \$4.7B by 2026⁴

1. *Curr Opin Nephrol Hypertens*. 2012 March ; 21(2): 163–170. doi:10.1097/MNH.0b013e32835021bd.

2. Study by Dr. Brian Helfand; cited at <https://consumer.healthday.com/men-s-health-information-24/male-hormones-health-news-389/most-men-with-erectile-dysfunction-don-t-seem-to-get-treatment-676114.html>

3. <https://doi.org/10.1111/jsm.12179>

4. <https://www.arizton.com/market-reports/erectile-dysfunction-market>

Men's Health Empowerment and Consumer Choice

- Petros Pharmaceuticals and its strategic alliances are committed, well-equipped and experienced in establishing new pathways to engage patients and consumers to help take control of their healthcare on their terms
- Concept options include

NSURE (FDA)

(Nonprescription Safe
Use Regulatory
Expansion)

Prescription to Over-
the-Counter (OTC)
switch
(subject to FDA
guidance and
approval)

Other emerging
technology that
supports non-
prescription
mechanisms

Portfolio Asset

- Distinct and Patent Protected (see Stendra.com)
- Currently in market and generating sales revenue
- Intentions to seek new frontier supporting greater consumer reach, control and access
- NSURE (see FDA guidance & advisory publications)
- Explore OTC or Non-prescription designation potential with FDA



STENDRA[®]
(avanafil) tablets

A photograph of a pharmacy interior. In the foreground, there are glass display cases filled with various medications, including boxes of Bepanthen, Clavin, and GS Condro Diamant. Behind the cases, there are more shelves stocked with a wide variety of drugs. A white service counter is visible on the right side of the image, with a computer monitor and a cash register on it. The pharmacy has a clean, professional appearance with yellow walls and bright lighting.

Potential First Over-the-counter (ED) Drug

- In February 2021, Petros formed a steering committee to develop expanded patient access initiatives, including non-prescription or Over-the-Counter (OTC) status strategies, for its Stendra® (avanafil) product

A Glimpse into Peyronie's Disease

- Peyronie's (pay-roe-NEEZ) disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections
- May impact an estimated 11 million** men in the US¹
- Current Treatment Options*
 - Series of Injections
 - Invasive surgery
 - Devices

*Options listed are among the few clinically proven treatments
(not inclusive of off-label or clinically unproven or FDA unapproved treatment options)

** Based on 11% of adult male population of ~100m

1. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D (2016) The Prevalence of Peyronie's Disease in the United States: A Population Based Study. PLoS ONE 11(2): e0150157. doi:10.1371/journal.pone.0150157

Nasdaq: PTPI

Peyronie's Disease Pilot Study Topical H-100 Gel

H-100 Gel is US patented

Pilot Study

Evaluating safety and efficacy of topically applied H-100 gel composed of Nicardipine, superoxide dismutase and emu oil for the treatment of acute phase Peyronie's disease (PD)

Placebo group showed no significant improvement except for mean stretched penile length (with an increase of 6.8%)

22 patients prospective, randomized, double-blind, placebo-controlled study

Mean pain level reduction of 85.7%

Mean stretched penile length increase of 22%

Mean curvature reduction of 40.8%

Candidate therapy subject to further clinical development & FDA review

Nasdaq: PTPI

Portfolio Assets & Development Pipeline

Timm Medical Device Business Unit Portfolio

(Currently in Market & Generating Sales Revenue)

- Osbon ErecAid Vacuum Erection Device (VED)
- PostVac Vacuum Erection Device (VED)

Drug Development Pipeline

Investigational topical compound for early phase Peyronie's disease

- One small double blind pilot study conducted with statistically significant improvements in intended endpoints
- Specific use designation concept within Peyronie's disease currently under review by FDA
- Pre-IND meeting to follow for official clinical development roadmap

If clinically proven and approved, at this time this would be the first FDA approved topical therapy for early phase Peyronie's disease



Osbon Esteem Manual



PTV Automatic 3000

Reputable Support & Strategic Alliances

- Petros has several relationships to help drive success. The support consists of strong financial and strategic alliances that share a commitment to advancing the men's health marketplace
- Together, John Shulman and Greg Bradley brought Plan B One-Step from a prescription only drug to an over-the-counter product – driving the #1 selling SKU in the U.S.



John Shulman

Founding Partner, Juggernaut
Capital Partners



Greg Bradley

President & CEO, Foundation
Consumer Healthcare



Management Team



John Shulman

Petros Pharmaceuticals
Executive Chairman
Principal and Founder of
Juggernaut CP



Cranford Pharmaceuticals, LLC



Greg Bradley

Petros Pharmaceuticals
Board Member, Current
President, & CEO,
Of FCH



GlaxoSmithKline
Consumer Healthcare



Fady Bactor

Petros Pharmaceuticals
President,
Chief Commercial Officer



Opportunity Summary

- Patented and trademarked Erectile Dysfunction (ED) drug called Stendra (avanafil) tablets
- Rapidly growing revenues
- Product roadmap designed to address unmet need in the market
- Potential to have first over-the-counter Erectile Dysfunction (ED) drug
- Experienced management team with experience at GSK, Novartis and Insight Pharma
- Strong balance sheet



STENDRA[®]
(avanafil) tablets



Contact

Jules Abraham

917-885-7378

pr@coreir.com

Nasdaq: PTPI